Bosses at Japanese pharma major Eisai (TYO: 4523) are angry at the exclusion of its oncology drug Lenvima (lenvatinib) from the Cancer Drugs Fund (CDF) in England.
First launched in 2011, the CDF is aimed at ensuring patients in England can get cancer drugs that are not routinely available on the National Health Service (NHS).
The fund is being re-launched this summer and, from July 29, a number of drugs will be immediately eligible to receive interim funding, subject to agreement from the relevant pharmaceutical companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze